Endoscopy-based management decreases the risk of postoperative recurrences in Crohn’s disease

Table 3 Univariate analysis of risk factors for clinical postoperative recurrence in Crohn’s disease

	Median time to clinical POR (mo)	HR [95%CI]	P value
Age		1.00 [0.99-1.01]	0.4
Age
< 35 yr	45.2	Reference
≥ 35 yr	30.2	1.25 [0.84-1.85]	0.27
Age at diagnosis
≤ 16 yr	38.1	Reference
16-40 yr	48.0	0.81 [0.43-1.54]	0.52
≥ 40 yr	30.2	1.03 [0.48-2.23]	0.93
Tobacco use
Non-smoker	45.2	Reference
Active smoker	43.7	1.00 [0.66-1.53]	0.98
Previous intestinal resection
No	51.0	Reference
Yes	26.6	1.62 [1.07-2.44]	0.02
Total resection length > 50 cm
No	38.1	Reference
Yes	33.4	1.20 [0.66-2.16]	0.55
Disease behavior (Montreal classification)
B1	84.5	Reference
B2	54.5	1.39 [0.48-4.00]	0.53
B3	28.9	1.61 [0.56-4.56]	0.37
Fistulizing Crohn’s disease (B3)
No	58.2	Reference
Yes	28.9	1.21 [0.81-1.78]	0.34
Perianal lesions
No	54.5	Reference
Yes	26.9	1.26 [0.85-1.86]	0.24
Type of perianal lesions
Non-fistulizing lesions	54.5	Reference
Fistula, abscess	20.5	1.46 [1.01-2.16]	0.05
Disease duration		1.00 [0.99-1.01]	0.31
Ileal resection > 50 cm
No	33.4	Reference
Yes	59.5	0.72 [0.26-2.02]	0.54
Prior exposure to anti-TNF therapy before surgery
No	48.0	Reference
Yes	24.0	2.64 [1.24-4.33]	0.007
Thiopurines therapy in prevention of clinical postoperative recurrence
No	44.8	Reference
Yes	43.7	1.14 [0.74-1.76]	0.53
Anti-TNF therapy in prevention of clinical postoperative recurrence
No	48.6	Reference
Yes	29.3	1.39 [0.88-2.20]	0.16
Period of surgery
1986-1999		Reference
2000-2015		1.71 [1.12-2.63]	0.013

CRP: C-reactive protein; TNF: Tumor necrosis factor.